CCNE1

UniProt ID: P24864
Organism: Homo sapiens
Review Status: IN PROGRESS
📝 Provide Detailed Feedback

Gene Description

CCNE1 encodes cyclin E1, a regulatory subunit of the cyclin-dependent kinase CDK2. Cyclin E1 binds and activates CDK2, driving phosphorylation of key substrates such as RB1 to promote the G1/S transition of the cell cycle and commitment to S-phase entry. Cyclin E1 itself has no catalytic activity; its role is to confer substrate specificity and temporal activation on CDK2. The protein is predominantly nuclear and its abundance is tightly regulated by SCF-FBXW7-dependent ubiquitin-mediated proteolysis, triggered by phosphodegron motifs phosphorylated by CDK2 and GSK3. CCNE1 amplification and overexpression are frequent in cancers, particularly high-grade serous ovarian cancer (~22% of TCGA cases), where they drive replication stress and genomic instability.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0000082 G1/S transition of mitotic cell cycle
IBA
GO_REF:0000033
ACCEPT
Summary: Core function. Cyclin E1 is the canonical regulator of G1/S transition via CDK2 activation. Extensively supported by phylogenetic inference (IBA) and all literature.
Reason: G1/S transition is the defining biological process for cyclin E1. The deep research (CCNE1-deep-research-falcon.md) confirms "Cyclin E1 is a non-enzymatic regulatory subunit whose primary molecular function is to bind and activate CDK2, thereby promoting late G1 progression and G1/S transition" (kasirzadeh2024targetingcdk2to). IBA annotations for such core functions are typically well-reviewed.
Supporting Evidence:
PMID:15838514
Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
GO:0005634 nucleus
IBA
GO_REF:0000033
ACCEPT
Summary: Cyclin E1 is a nuclear protein as established by multiple lines of evidence including the UniProt record which states "Nucleus" with experimental evidence from PMID:7739542.
Reason: Nuclear localization of cyclin E1 is well established. UniProt states "SUBCELLULAR LOCATION: Nucleus" with experimental evidence. IBA annotation is consistent.
Supporting Evidence:
PMID:19942931
Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S phase cell cycle regulator
GO:0005737 cytoplasm
IBA
GO_REF:0000033
ACCEPT
Summary: Cyclin E1 is also found in the cytoplasm. IHC studies show both nuclear and cytoplasmic localization, and the deep research notes nucleocytoplasmic shuttling.
Reason: Cytoplasmic localization is supported by IHC evidence showing "cytoplasmic cyclin E1 was frequently high (70% high vs 30% low)" in ovarian cancer (lashen2024theclinicopathologicalsignificance). Cyclin E and CDK2 are known to shuttle between nucleus and cytoplasm (chen2025targetingcdk2and). IBA annotation is consistent.
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
IBA
GO_REF:0000033
ACCEPT
Summary: Core molecular function of cyclin E1. It is a non-enzymatic regulatory subunit that binds and activates CDK2, a cyclin-dependent serine/threonine kinase.
Reason: This is the defining molecular function of cyclin E1. It does not have kinase activity itself but activates CDK2. PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2." The IBA annotation is at the right level of specificity.
Supporting Evidence:
PMID:8207080
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin
GO:0097134 cyclin E1-CDK2 complex
IBA
GO_REF:0000033
ACCEPT
Summary: Cyclin E1 is a defining component of the cyclin E1-CDK2 complex. Crystal structure of the complex has been solved (PDB:1W98, PMID:15660127).
Reason: UniProt states "Interacts with CDK2 protein kinase to form a serine/threonine kinase holoenzyme complex." Multiple crystal structures confirm this (PDB:1W98). ComplexPortal entry CPX-2015 explicitly defines the Cyclin E1-CDK2 complex.
GO:0005815 microtubule organizing center
IBA
GO_REF:0000033
ACCEPT
Summary: Cyclin E-CDK2 is known to play a role in centrosome duplication, and localization to centrosomes (microtubule organizing centers) has been reported in the literature for cyclin E in model organisms. The IBA annotation reflects phylogenetic inference from orthologs.
Reason: Cyclin E-CDK2 activity is required for centrosome duplication, and cyclin E has been shown to localize to centrosomes. This is supported by the broader cell cycle biology literature and is phylogenetically conserved (IBA).
GO:1900087 positive regulation of G1/S transition of mitotic cell cycle
IBA
GO_REF:0000033
ACCEPT
Summary: Cyclin E1 positively regulates G1/S transition by activating CDK2, which phosphorylates RB1 to release E2F transcription factors for S-phase gene expression.
Reason: This is a core function. The deep research confirms "CDK2-cyclin E activity promotes S-phase entry in large part by phosphorylating RB, enabling E2F transcriptional activation" (kasirzadeh2024targetingcdk2to). The IBA annotation is at the right level of specificity.
Supporting Evidence:
PMID:15838514
Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
GO:0005634 nucleus
IEA
GO_REF:0000120
ACCEPT
Summary: IEA annotation for nuclear localization, consistent with the IBA and IDA annotations for the same term.
Reason: Redundant with IBA and IDA annotations but not wrong. Nuclear localization is well established for cyclin E1.
GO:0051301 cell division
IEA
GO_REF:0000043
ACCEPT
Summary: IEA annotation from UniProt keyword mapping. Cell division is a broad term that encompasses the G1/S transition role of cyclin E1.
Reason: While broader than the more specific G1/S transition annotations, this IEA is not wrong. Cyclin E1 is clearly involved in cell division. The UniProt record includes "Cell cycle; Cell division" as keywords.
GO:0005515 protein binding
IPI
PMID:10330164
Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions wi...
MARK AS OVER ANNOTATED
Summary: Interaction with p300 coactivator. PMID:10330164 shows cyclin E-Cdk2 binds to the COOH-terminal region of p300, though this is described as a complex interaction (cyclin E-Cdk2 rather than cyclin E alone).
Reason: The term "protein binding" is uninformative. The actual finding is a specific interaction of cyclin E-Cdk2 complex with the p300 coactivator. However, the GO guidelines discourage generic protein binding annotations.
Supporting Evidence:
PMID:10330164
the COOH-terminal region of p300 binds to cyclin E-cyclin-dependent kinase 2 (cyclin E-Cdk2) and TFIIB
GO:0005515 protein binding
IPI
PMID:11533444
Phosphorylation-dependent ubiquitination of cyclin E by the ...
MARK AS OVER ANNOTATED
Summary: Interaction with FBXW7 (SCFFbw7) for phosphorylation-dependent ubiquitination. This is a well-characterized substrate-E3 ligase interaction.
Reason: The term "protein binding" is uninformative. The actual interaction is between cyclin E and FBXW7 as part of SCF-mediated ubiquitination. This is better captured by other annotations related to cyclin E degradation.
Supporting Evidence:
PMID:11533444
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase
GO:0005515 protein binding
IPI
PMID:16223725
The loss of PIN1 deregulates cyclin E and sensitizes mouse e...
MARK AS OVER ANNOTATED
Summary: Interaction with PIN1 prolyl isomerase. PIN1 regulates cyclin E stability.
Reason: Generic protein binding is uninformative. The actual finding is PIN1 regulation of cyclin E stability.
Supporting Evidence:
PMID:16223725
The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability
GO:0005515 protein binding
IPI
PMID:16431923
The nucleocapsid protein of severe acute respiratory syndrom...
MARK AS OVER ANNOTATED
Summary: Interaction with SARS-CoV nucleocapsid protein, which inhibits cyclin-CDK activity. This is a viral pathogen interaction, not a core function.
Reason: Generic protein binding is uninformative. The interaction is with a viral protein (SARS-CoV nucleocapsid) and represents pathogen interference with cell cycle, not a core function of cyclin E1.
Supporting Evidence:
PMID:16431923
The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells
GO:0005515 protein binding
IPI
PMID:16504183
Regulation of the transcription factor FOXM1c by Cyclin E/CD...
MARK AS OVER ANNOTATED
Summary: Interaction with FOXM1c transcription factor, regulated by Cyclin E/CDK2. UniProt lists FOXM1 as an interaction partner.
Reason: Generic protein binding is uninformative. The actual finding is regulation of FOXM1c by cyclin E/CDK2 complex phosphorylation.
Supporting Evidence:
PMID:16504183
Regulation of the transcription factor FOXM1c by Cyclin E/CDK2
GO:0005515 protein binding
IPI
PMID:16721056
G1/S Cyclins interact with regulatory subunit of PKA via A-k...
MARK AS OVER ANNOTATED
Summary: Interaction with AKAP95 (A-kinase anchoring protein). G1/S cyclins interact with PKA regulatory subunit via AKAP95.
Reason: Generic protein binding is uninformative. UniProt lists AKAP8 as an interaction partner.
Supporting Evidence:
PMID:16721056
G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring protein, AKAP95
GO:0005515 protein binding
IPI
PMID:16765349
Increased p21 expression and complex formation with cyclin E...
MARK AS OVER ANNOTATED
Summary: Interaction with p21 (CDKN1A) in retinoid-induced apoptosis. p21 is a well-known CDK inhibitor that forms complexes with cyclin E/CDK2.
Reason: Generic protein binding is uninformative. The cyclin E-CDK2-p21 interaction is a core regulatory mechanism but should be annotated more specifically. UniProt lists CDKN1A with 11 experiments.
Supporting Evidence:
PMID:16765349
Increased p21 expression and complex formation with cyclin E/CDK2 in retinoid-induced pre-B lymphoma cell apoptosis
GO:0005515 protein binding
IPI
PMID:17254966
Cdk-inhibitory activity and stability of p27Kip1 are directl...
MARK AS OVER ANNOTATED
Summary: Interaction with p27Kip1 (CDKN1B). This is a key CDK inhibitor that regulates cyclin E-CDK2 activity.
Reason: Generic protein binding is uninformative. The cyclin E-CDK2-p27 interaction is well characterized. UniProt lists CDKN1B with 12 experiments.
Supporting Evidence:
PMID:17254966
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases
GO:0005515 protein binding
IPI
PMID:17254967
p27 phosphorylation by Src regulates inhibition of cyclin E-...
MARK AS OVER ANNOTATED
Summary: Another study on p27-cyclin E-Cdk2 interaction, showing Src-dependent phosphorylation of p27 regulates inhibition of cyclin E-Cdk2.
Reason: Generic protein binding is uninformative. This is the same well-characterized p27-cyclin E-CDK2 interaction.
Supporting Evidence:
PMID:17254967
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2
GO:0005515 protein binding
IPI
PMID:17525332
ATM and ATR substrate analysis reveals extensive protein net...
MARK AS OVER ANNOTATED
Summary: Large-scale ATM/ATR substrate analysis. This is a high-throughput study identifying proteins in DNA damage response networks, not a focused study on cyclin E function.
Reason: Generic protein binding from a high-throughput study. Does not provide specific information about cyclin E1 function.
Supporting Evidence:
PMID:17525332
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
GO:0005515 protein binding
IPI
PMID:19470470
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA ...
MARK AS OVER ANNOTATED
Summary: Study on RSK1-p27Kip1 phosphorylation. Cyclin E is mentioned as a binding partner of p27 but the study focuses on RSK1 function.
Reason: Generic protein binding is uninformative. The study focuses on RSK1 regulation of p27, with cyclin E as a known interactor.
Supporting Evidence:
PMID:19470470
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility
GO:0005515 protein binding
IPI
PMID:21092281
HTLV-I p30 inhibits multiple S phase entry checkpoints, decr...
MARK AS OVER ANNOTATED
Summary: HTLV-I p30 decreases cyclin E-CDK2 interactions. This is a viral interference study.
Reason: Generic protein binding is uninformative. This describes viral pathogen interference with cyclin E-CDK2, not a core function.
Supporting Evidence:
PMID:21092281
HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression
GO:0005515 protein binding
IPI
PMID:21952639
NIRF constitutes a nodal point in the cell cycle network and...
MARK AS OVER ANNOTATED
Summary: Interaction with UHRF2 (NIRF), which ubiquitinates cyclin E1. UniProt confirms this interaction with 4 experiments.
Reason: Generic protein binding is uninformative. The actual interaction is a substrate-E3 ligase relationship where UHRF2 ubiquitinates cyclin E1. UniProt states "Interacts directly with UHRF2; the interaction ubiquitinates CCNE1."
Supporting Evidence:
PMID:21952639
the ubiquitin ligase NIRF (also known as UHRF2), which induces G1 arrest, interacts with multiple cell cycle proteins including cyclins (A2, B1, D1 and E1), p53 and pRB, and ubiquitinates cyclins D1 and E1
GO:0005515 protein binding
IPI
PMID:21988832
Toward an understanding of the protein interaction network o...
MARK AS OVER ANNOTATED
Summary: High-throughput protein interaction study of the human liver. Not a focused study on cyclin E1 function.
Reason: Generic protein binding from a large-scale interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:21988832
Toward an understanding of the protein interaction network of the human liver
GO:0005515 protein binding
IPI
PMID:23455922
Interlaboratory reproducibility of large-scale human protein...
MARK AS OVER ANNOTATED
Summary: Large-scale AP-MS reproducibility study. Not a focused study on cyclin E1.
Reason: Generic protein binding from a high-throughput methods study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:23455922
Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS
GO:0005515 protein binding
IPI
PMID:23602568
The protein interaction landscape of the human CMGC kinase g...
MARK AS OVER ANNOTATED
Summary: CMGC kinase group interactome study. CDK2 is a CMGC kinase, so cyclin E1 would be identified as an interactor.
Reason: Generic protein binding from a kinase interactome study. The cyclin E-CDK2 interaction is already well captured by more specific annotations.
Supporting Evidence:
PMID:23602568
The protein interaction landscape of the human CMGC kinase group
GO:0005515 protein binding
IPI
PMID:23853094
Foxp3 protein stability is regulated by cyclin-dependent kin...
MARK AS OVER ANNOTATED
Summary: Foxp3 stability regulation by CDK2. The study shows CDK2 phosphorylates Foxp3, with cyclin E as the activating partner.
Reason: Generic protein binding is uninformative. The actual biology is CDK2 phosphorylation of Foxp3, where cyclin E1 is the activating cyclin partner.
Supporting Evidence:
PMID:23853094
Foxp3 protein stability is regulated by cyclin-dependent kinase 2
GO:0005515 protein binding
IPI
PMID:24358021
Polycomb protein SCML2 regulates the cell cycle by binding a...
MARK AS OVER ANNOTATED
Summary: SCML2 binding to CDK/CYCLIN/p21 complexes. Cyclin E is one of the cyclins in such complexes.
Reason: Generic protein binding is uninformative. The study describes SCML2 modulating CDK/cyclin/p21 complexes, with cyclin E as one component.
Supporting Evidence:
PMID:24358021
Polycomb protein SCML2 regulates the cell cycle by binding and modulating CDK/CYCLIN/p21 complexes
GO:0005515 protein binding
IPI
PMID:25241761
Using an in situ proximity ligation assay to systematically ...
MARK AS OVER ANNOTATED
Summary: In situ proximity ligation assay (PLA) study for profiling endogenous protein-protein interactions.
Reason: Generic protein binding from a methods-focused study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:25241761
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network
GO:0005515 protein binding
IPI
PMID:25852190
Integrative analysis of kinase networks in TRAIL-induced apo...
MARK AS OVER ANNOTATED
Summary: Kinase network analysis in TRAIL-induced apoptosis. High-throughput study.
Reason: Generic protein binding from a high-throughput network analysis study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:25852190
Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy
GO:0005515 protein binding
IPI
PMID:28514442
Architecture of the human interactome defines protein commun...
MARK AS OVER ANNOTATED
Summary: Large-scale human interactome architecture study.
Reason: Generic protein binding from a large-scale interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:28514442
Architecture of the human interactome defines protein communities and disease networks
GO:0005515 protein binding
IPI
PMID:32296183
A reference map of the human binary protein interactome.
MARK AS OVER ANNOTATED
Summary: Binary protein interactome reference map.
Reason: Generic protein binding from a large-scale interactome mapping study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:32296183
A reference map of the human binary protein interactome
GO:0005515 protein binding
IPI
PMID:33961781
Dual proteome-scale networks reveal cell-specific remodeling...
MARK AS OVER ANNOTATED
Summary: Dual proteome-scale interactome study showing cell-specific remodeling.
Reason: Generic protein binding from a large-scale interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:33961781
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome
GO:0005515 protein binding
IPI
PMID:34591612
A protein interaction landscape of breast cancer.
MARK AS OVER ANNOTATED
Summary: Protein interaction landscape of breast cancer.
Reason: Generic protein binding from a tissue-specific interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:34591612
A protein interaction landscape of breast cancer
GO:0005515 protein binding
IPI
PMID:35271311
OpenCell: Endogenous tagging for the cartography of human ce...
MARK AS OVER ANNOTATED
Summary: OpenCell endogenous tagging and cartography study.
Reason: Generic protein binding from a large-scale cellular organization study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:35271311
OpenCell: Endogenous tagging for the cartography of human cellular organization
GO:0005515 protein binding
IPI
PMID:35512704
Systematic discovery of mutation-directed neo-protein-protei...
MARK AS OVER ANNOTATED
Summary: Mutation-directed neo-protein-protein interactions in cancer.
Reason: Generic protein binding from a high-throughput cancer study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:35512704
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
GO:0005515 protein binding
IPI
PMID:40205054
Multimodal cell maps as a foundation for structural and func...
MARK AS OVER ANNOTATED
Summary: Multimodal cell maps study.
Reason: Generic protein binding from a large-scale cellular mapping study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:40205054
Multimodal cell maps as a foundation for structural and functional genomics
GO:0005515 protein binding
IPI
PMID:8553588
Human papillomavirus E7 oncoproteins bind a single form of c...
MARK AS OVER ANNOTATED
Summary: HPV E7 oncoproteins bind cyclin E in a complex with CDK2 and p107. This represents viral oncogene interaction with the cyclin E-CDK2 complex.
Reason: Generic protein binding is uninformative. The actual finding involves viral E7 oncoprotein binding to cyclin E-CDK2-p107 complexes, which is a pathogen interaction, not a core function.
Supporting Evidence:
PMID:8553588
Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107
GO:0005515 protein binding
IPI
PMID:8756624
Cyclin-binding motifs are essential for the function of p21C...
MARK AS OVER ANNOTATED
Summary: Cyclin-binding motifs essential for p21CIP1 function. This demonstrates the p21-cyclin E interaction is functionally important.
Reason: Generic protein binding is uninformative. The study reveals specific cyclin-binding motifs in p21, but the annotation should be more specific than "protein binding."
Supporting Evidence:
PMID:8756624
Cyclin-binding motifs are essential for the function of p21CIP1
GO:0005515 protein binding
IPI
PMID:9840943
Cyclin E2, a novel human G1 cyclin and activating partner of...
MARK AS OVER ANNOTATED
Summary: Cyclin E2 discovery paper that also characterizes cyclin E1 interactions with CDK2 and CDK3.
Reason: Generic protein binding is uninformative. The CDK2 interaction is already captured by the more specific cyclin E1-CDK2 complex annotation (GO:0097134).
Supporting Evidence:
PMID:9840943
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins
GO:0000307 cyclin-dependent protein kinase holoenzyme complex
IEA
GO_REF:0000107
ACCEPT
Summary: IEA annotation for CDK holoenzyme complex membership. This is a more general parent of cyclin E1-CDK2 complex (GO:0097134).
Reason: While more general than GO:0097134 (cyclin E1-CDK2 complex), this IEA annotation is not wrong. Cyclin E1 is indeed a component of a cyclin-dependent protein kinase holoenzyme complex (the CDK2 holoenzyme). It is acceptable for IEA annotations to be broader.
GO:0016301 kinase activity
IEA
GO_REF:0000107
REMOVE
Summary: IEA annotation attributing kinase activity to cyclin E1. However, cyclin E1 is NOT a kinase; it is a regulatory subunit that activates CDK2.
Reason: Cyclin E1 does not have kinase activity itself. It is a non-enzymatic regulatory subunit that binds and activates CDK2. PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2." The kinase activity belongs to CDK2, not cyclin E1. The correct MF annotation is GO:0016538 (cyclin-dependent protein serine/threonine kinase regulator activity), which is already annotated. This IEA annotation is incorrect and should be removed.
Supporting Evidence:
PMID:8207080
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
IEA
GO_REF:0000107
ACCEPT
Summary: IEA annotation consistent with the IBA annotation for the same term. This is the correct molecular function for cyclin E1.
Reason: Consistent with the IBA annotation. This is the defining molecular function of cyclin E1 as a CDK2 regulatory subunit.
GO:0019901 protein kinase binding
IEA
GO_REF:0000107
ACCEPT
Summary: IEA annotation for protein kinase binding. Cyclin E1 does bind CDK2 (a protein kinase), so this is technically correct but vague.
Reason: Cyclin E1 binds CDK2, which is a protein kinase. UniProt states "Interacts with CDK2 protein kinase to form a serine/threonine kinase holoenzyme complex" (PMID:15660127). While more informative terms exist (GO:0016538), this IEA annotation is not incorrect and can be retained as a broader term.
GO:0097134 cyclin E1-CDK2 complex
IEA
GO_REF:0000107
ACCEPT
Summary: IEA annotation consistent with IBA annotation for the same term.
Reason: Consistent with the IBA annotation. Cyclin E1 is a defining component of the cyclin E1-CDK2 complex (ComplexPortal CPX-2015).
GO:0005654 nucleoplasm
IDA
GO_REF:0000052
ACCEPT
Summary: IDA annotation from HPA immunofluorescence data showing nucleoplasmic localization.
Reason: Nucleoplasmic localization is consistent with cyclin E1 being a nuclear protein that functions in cell cycle regulation within the nucleus. This is supported by multiple lines of evidence.
GO:0000082 G1/S transition of mitotic cell cycle
NAS
PMID:15838514
Cyclin E in normal and neoplastic cell cycles.
ACCEPT
Summary: NAS annotation from a review article on cyclin E in normal and neoplastic cell cycles. Confirms the core function of cyclin E1 in G1/S transition.
Reason: Core function annotation supported by review literature. PMID:15838514 states "Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle."
Supporting Evidence:
PMID:15838514
Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
GO:0000082 G1/S transition of mitotic cell cycle
IMP
PMID:23083510
miR-16 inhibits the proliferation and angiogenesis-regulatin...
ACCEPT
Summary: IMP annotation from a study showing miR-16 targets cyclin E1 to inhibit mesenchymal stem cell proliferation and induce cell cycle arrest. Cyclin E1 knockdown/downregulation caused cell cycle arrest, supporting its role in G1/S transition.
Reason: The study shows that miR-16 targets cyclin E1, and over-expression of miR-16 "inhibited the proliferation and migration of decidua-derived mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1" (PMID:23083510). This supports cyclin E1 involvement in G1/S transition.
Supporting Evidence:
PMID:23083510
over-expressed miR-16 inhibited the proliferation and migration of decidua-derived mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1
GO:1902462 positive regulation of mesenchymal stem cell proliferation
IMP
PMID:23083510
miR-16 inhibits the proliferation and angiogenesis-regulatin...
KEEP AS NON CORE
Summary: IMP annotation from miR-16 study in pre-eclampsia. While cyclin E1 promotes proliferation of mesenchymal stem cells (shown by miR-16 targeting), this is a very specific biological context (decidual MSCs in pre-eclampsia) rather than a core function.
Reason: Cyclin E1 does promote proliferation in MSCs as shown by the miR-16 study, but this is a pleiotropic effect of its general cell cycle role in a specific cell type context, not a core evolved function. The annotation is technically supported but represents a context-specific manifestation.
Supporting Evidence:
PMID:23083510
over-expressed miR-16 inhibited the proliferation and migration of decidua-derived mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1
GO:0000082 G1/S transition of mitotic cell cycle
IMP
PMID:25732226
MicroRNA-30c-2-3p negatively regulates NF-ÎșB signaling and c...
ACCEPT
Summary: IMP annotation from study showing miR-30c-2-3p targets CCNE1 in breast cancer cells. Inhibition of CCNE1 phenocopied effects on cell proliferation.
Reason: The study confirms that CCNE1 downregulation affects cell cycle progression. "inhibition of CCNE1 phenocopied the effects on cell proliferation" (PMID:25732226). Supports G1/S transition role.
Supporting Evidence:
PMID:25732226
inhibition of CCNE1 phenocopied the effects on cell proliferation
GO:0005515 protein binding
IPI
PMID:21540187
Inhibitor of cyclin-dependent kinase (CDK) interacting with ...
MARK AS OVER ANNOTATED
Summary: Interaction with INCA1 (inhibitor of CDK interacting with cyclin A1). UniProt confirms "Interacts with INCA1" (PMID:21540187).
Reason: Generic protein binding is uninformative. The actual interaction is between cyclin E1 and INCA1, a CDK inhibitor. UniProt confirms this interaction.
Supporting Evidence:
PMID:21540187
we identified INCA1 as an interaction partner and a substrate of cyclin A1 in complex with CDK2
GO:0005634 nucleus
IDA
PMID:19942931
Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates tropho...
ACCEPT
Summary: Nuclear localization of cyclin E1 observed in trophoblast cells. The study shows Mtd-L colocalizes with cyclin E1 in the nuclear compartment.
Reason: Nuclear localization confirmed by immunofluorescence in proliferating trophoblast cells. "Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S phase cell cycle regulator" (PMID:19942931). Consistent with UniProt annotation.
Supporting Evidence:
PMID:19942931
Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S phase cell cycle regulator
GO:0005515 protein binding
IPI
PMID:17434132
Structure of a Fbw7-Skp1-cyclin E complex: multisite-phospho...
MARK AS OVER ANNOTATED
Summary: Structural study of Fbw7-Skp1-cyclin E complex. Demonstrates the molecular basis for cyclin E recognition by SCF-FBXW7 for ubiquitin-mediated degradation. This is a well-characterized interaction.
Reason: Generic protein binding is uninformative. The actual finding is the structural basis for FBXW7 recognition of phosphorylated cyclin E degrons. This interaction is critical for cyclin E turnover but "protein binding" does not capture the functional significance.
Supporting Evidence:
PMID:17434132
Cyclin E degradation is triggered by multisite phosphorylation, which induces binding to the SCF(Fbw7) ubiquitin ligase complex
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-187520
ACCEPT
Summary: Reactome TAS annotation for nucleoplasmic localization, from the Cyclin E/A:Cdk2-mediated phosphorylation of p27/p21 reaction.
Reason: Cyclin E-CDK2 mediates phosphorylation of p27/p21 in the nucleoplasm as part of the Skp2-mediated degradation pathway. Consistent with nuclear function.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-187552
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from binding of phospho-p27/p21 to SCF(Skp2):Cks1 complex.
Reason: Consistent with established nucleoplasmic function of cyclin E-CDK2 complex.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-187574
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from degradation of ubiquitinated p27/p21 by 26S proteasome.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-187575
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from ubiquitination of phospho-p27/p21.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-188350
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from CAK-mediated phosphorylation of Cyclin E:Cdk2.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-188386
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from association of Rb with Cyclin E:Cdk2 complexes.
Reason: Consistent with nucleoplasmic localization for RB1 phosphorylation by cyclin E-CDK2.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-188390
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from Cyclin E:CDK2-mediated phosphorylation of RB1.
Reason: Consistent with nucleoplasmic localization for the core function of RB1 phosphorylation.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-69005
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from Cdc6 phosphorylation by CDK.
Reason: Consistent with nucleoplasmic localization. Cdc6 phosphorylation by cyclin E-CDK2 is part of DNA replication licensing.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-69195
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from phosphorylation of Cyclin E:CDK2 complexes by WEE1.
Reason: Consistent with nucleoplasmic localization during cell cycle checkpoint regulation.
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-69199
ACCEPT
Summary: Reactome TAS annotation for nucleoplasm, from dephosphorylation of Cyclin E:Cdk2 complexes by Cdc25A.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
GO:0005829 cytosol
TAS
Reactome:R-HSA-157906
ACCEPT
Summary: Reactome TAS annotation for cytosol, from translocation of Cyclin E:Cdk2 complex to the nucleus. Cyclin E-CDK2 is present in the cytosol before nuclear translocation.
Reason: Cyclin E-CDK2 complexes form in the cytosol before translocation to the nucleus. The Reactome reaction R-HSA-157906 specifically describes this translocation, implying cytosolic presence.
GO:0005829 cytosol
TAS
Reactome:R-HSA-69191
ACCEPT
Summary: Reactome TAS annotation for cytosol, from formation of Cyclin E:Cdk2 complexes.
Reason: Cyclin E-CDK2 complex formation occurs in the cytosol. Consistent with known biology of cyclin-CDK complex assembly.
GO:0005829 cytosol
TAS
Reactome:R-HSA-8961846
ACCEPT
Summary: Reactome TAS annotation for cytosol, from CCNE1 gene transcription stimulated by E2F1. This annotation seems to be about the gene product being present in cytosol in the context of its transcriptional regulation.
Reason: While the Reactome reaction is about transcriptional regulation, cyclin E1 protein is synthesized in the cytosol. Consistent with cytoplasmic localization evidence.
GO:0005829 cytosol
TAS
Reactome:R-HSA-9706390
ACCEPT
Summary: Reactome TAS annotation for cytosol from RHOBTB3 interaction at trans-Golgi network. This is a less well-characterized interaction.
Reason: While the RHOBTB3 interaction context is less well characterized for cyclin E1, cytosolic presence is consistent with known nucleocytoplasmic shuttling of cyclin E.
GO:0006468 protein phosphorylation
IMP
PMID:10500095
Cullin-3 targets cyclin E for ubiquitination and controls S ...
MODIFY
Summary: PMID:10500095 describes Cullin-3 targeting cyclin E for ubiquitination. The paper discusses cyclin E phosphorylation as a signal for degradation, and cyclin E-CDK2 complex kinase activity, but cyclin E itself does not catalyze phosphorylation. Cyclin E1 is a regulatory subunit, not a kinase.
Reason: Cyclin E1 does not catalyze protein phosphorylation itself. It is a non-enzymatic regulatory subunit that activates CDK2. The annotation should be modified to reflect that cyclin E1 regulates protein kinase activity rather than directly performing phosphorylation. PMID:10500095 discusses "cyclin E-Cdk2 complexes" where CDK2 is the catalytic subunit. The paper actually focuses on "Cyclin E is an unstable protein that is degraded in a ubiquitin- and proteasome-dependent pathway."
Supporting Evidence:
PMID:10500095
Cyclin E is an unstable protein that is degraded in a ubiquitin- and proteasome- dependent pathway
GO:0005634 nucleus
IDA
PMID:16109376
The bromodomain protein Brd4 is a positive regulatory compon...
ACCEPT
Summary: PMID:16109376 is about the bromodomain protein Brd4 and P-TEFb, not directly about cyclin E1. Brd4 interacts with cyclinT1 and Cdk9. The reference appears questionable for a CCNE1 nuclear localization annotation, as the paper primarily concerns cyclinT1/Cdk9. However, nuclear localization of cyclin E1 is well established by multiple other lines of evidence, including UniProt annotation with PMID:7739542 and IDA from PMID:19942931.
Reason: Although the specific reference PMID:16109376 may be a curatorial error (the paper focuses on Brd4/P-TEFb/cyclinT1/Cdk9 rather than cyclin E1), the nuclear localization of CCNE1 itself is unambiguously established. UniProt states "SUBCELLULAR LOCATION: Nucleus" with experimental evidence, and multiple other IDA annotations confirm nuclear localization (PMID:19942931). The annotation conclusion is correct even if the cited reference is questionable.
Supporting Evidence:
PMID:16109376
Proteomic analysis revealed that Brd4 interacts with cyclinT1 and Cdk9 that constitutes core positive transcription elongation factor b (P-TEFb)
GO:0005515 protein binding
IPI
PMID:9891079
Cyclin E associates with BAF155 and BRG1, components of the ...
MARK AS OVER ANNOTATED
Summary: Interaction with BAF155 and BRG1, components of the SWI-SNF chromatin remodeling complex. Cyclin E associates with these components and modulates BRG1-induced growth arrest.
Reason: Generic protein binding is uninformative. The actual finding is a specific interaction between cyclin E and SWI-SNF complex components (BAF155, BRG1) that may modulate chromatin remodeling during cell cycle progression.
Supporting Evidence:
PMID:9891079
BRG1 and BAF155, mammalian homologs of yeast SWI2 and SWI3, respectively, are found in cyclin E complexes and are phosphorylated by cyclin E-associated kinase activity
GO:0000082 G1/S transition of mitotic cell cycle
NAS
PMID:8207080
Alternative splicing of human cyclin E.
ACCEPT
Summary: NAS annotation from the alternative splicing paper. The paper establishes cyclin E as a G1 cyclin that activates CDK2 for S-phase entry.
Reason: PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin." Core function annotation.
Supporting Evidence:
PMID:8207080
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin

Core Functions

Cyclin E1 functions as a regulatory subunit that binds and activates CDK2 (cyclin-dependent kinase 2), forming the cyclin E1-CDK2 holoenzyme complex. The cyclin E1-CDK2 complex phosphorylates RB1, releasing E2F transcription factors to activate S-phase gene expression, thereby driving the G1/S transition of the mitotic cell cycle.

Supporting Evidence:
  • PMID:15838514
    Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
  • PMID:8207080
    Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin

References

Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
Gene Ontology annotation based on curation of immunofluorescence data
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Combined Automated Annotation using Multiple IEA Methods
Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions with a common domain of the p300 coactivator.
Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells.
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.
Cyclin E in normal and neoplastic cell cycles.
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability.
The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells.
Regulation of the transcription factor FOXM1c by Cyclin E/CDK2.
G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring protein, AKAP95.
Increased p21 expression and complex formation with cyclin E/CDK2 in retinoid-induced pre-B lymphoma cell apoptosis.
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases.
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.
Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases.
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.
Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates trophoblast cell proliferation during human placental development and in preeclampsia.
HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression.
Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1 (INCA1) regulates proliferation and is repressed by oncogenic signaling.
NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor.
Toward an understanding of the protein interaction network of the human liver.
miR-16 inhibits the proliferation and angiogenesis-regulating potential of mesenchymal stem cells in severe pre-eclampsia.
Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS.
The protein interaction landscape of the human CMGC kinase group.
Foxp3 protein stability is regulated by cyclin-dependent kinase 2.
Polycomb protein SCML2 regulates the cell cycle by binding and modulating CDK/CYCLIN/p21 complexes.
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.
MicroRNA-30c-2-3p negatively regulates NF-ÎșB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer.
Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy.
Architecture of the human interactome defines protein communities and disease networks.
A reference map of the human binary protein interactome.
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
A protein interaction landscape of breast cancer.
OpenCell: Endogenous tagging for the cartography of human cellular organization.
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Multimodal cell maps as a foundation for structural and functional genomics.
Alternative splicing of human cyclin E.
Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107.
Cyclin-binding motifs are essential for the function of p21CIP1.
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins.
Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest.
Reactome:R-HSA-157906
Translocation of Cyclin E:Cdk2 complex to the nucleus
Reactome:R-HSA-187520
Cyclin E/A:Cdk2-mediated phosphorylation of p27/p21
Reactome:R-HSA-187552
Binding of phospho-p27/p21:Cdk2:Cyclin E/A to the SCF(Skp2):Cks1 complex
Reactome:R-HSA-187574
Degradation of ubiquitinated p27/p21 by the 26S proteasome
Reactome:R-HSA-187575
Ubiquitination of phospho-p27/p21
Reactome:R-HSA-188350
CAK-mediated phosphorylation of Cyclin E:Cdk2
Reactome:R-HSA-188386
Association of Rb with Cyclin E:Cdk2 complexes
Reactome:R-HSA-188390
Cyclin E:CDK2-mediated phosphorylation of RB1
Reactome:R-HSA-69005
Cdc6 protein is phosphorylated by CDK
Reactome:R-HSA-69191
Formation of Cyclin E:Cdk2 complexes
Reactome:R-HSA-69195
Phosphorylation of Cyclin E:CDK2 complexes by WEE1
Reactome:R-HSA-69199
Dephosphorylation of Cyclin E:Cdk2 complexes by Cdc25A
Reactome:R-HSA-8961846
CCNE1 gene transcription is stimulated by E2F1
Reactome:R-HSA-9706390
RHOBTB3 binds interacting proteins at trans-Golgi network

📚 Additional Documentation

Deep Research Falcon

(CCNE1-deep-research-falcon.md)

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-03-06T03:10:18.530953'
end_time: '2026-03-06T03:23:48.672523'
duration_seconds: 810.14
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: CCNE1
gene_symbol: CCNE1
uniprot_accession: P24864
protein_description: 'RecName: Full=G1/S-specific cyclin-E1;'
gene_info: Name=CCNE1; Synonyms=CCNE;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the cyclin family. Cyclin E subfamily.
protein_domains: Cyclin. (IPR039361); Cyclin-like_dom. (IPR013763); Cyclin-like_sf.
(IPR036915); Cyclin_C-dom. (IPR004367); Cyclin_N. (IPR006671)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 23


Question

Gene Research for Functional Annotation

⚠ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P24864
  • Protein Description: RecName: Full=G1/S-specific cyclin-E1;
  • Gene Information: Name=CCNE1; Synonyms=CCNE;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the cyclin family. Cyclin E subfamily.
  • Key Domains: Cyclin. (IPR039361); Cyclin-like_dom. (IPR013763); Cyclin-like_sf. (IPR036915); Cyclin_C-dom. (IPR004367); Cyclin_N. (IPR006671)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "CCNE1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'CCNE1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene CCNE1 (gene ID: CCNE1, UniProt: P24864) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P24864
  • Protein Description: RecName: Full=G1/S-specific cyclin-E1;
  • Gene Information: Name=CCNE1; Synonyms=CCNE;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the cyclin family. Cyclin E subfamily.
  • Key Domains: Cyclin. (IPR039361); Cyclin-like_dom. (IPR013763); Cyclin-like_sf. (IPR036915); Cyclin_C-dom. (IPR004367); Cyclin_N. (IPR006671)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "CCNE1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'CCNE1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene CCNE1 (gene ID: CCNE1, UniProt: P24864) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human CCNE1 (Cyclin E1; UniProt P24864) — Functional Annotation, Regulation, Localization, and Clinical Relevance

1) Target verification (gene/protein identity)

The literature set analyzed corresponds to human CCNE1 (cyclin E1), consistent with UniProt accession P24864. In particular, Zhang et al. studied the full-length human CCNE1 gene product in the context of the cyclin E1:CDK2 complex and mapped a cryptic allosteric pocket at the CCNE1:CDK2 interface near CCNE1 residue N112, confirming that “CCNE1” in these sources refers to the canonical human cyclin E1 protein (zhang2025anallostericcyclin pages 1-3).

2) Key concepts and current understanding (functional definition)

2.1 Core molecular function

Cyclin E1 is a non-enzymatic regulatory subunit (cyclin) whose primary molecular function is to bind and activate CDK2, thereby promoting late G1 progression and G1/S transition. Mechanistically, CDK2–cyclin E activity promotes S-phase entry in large part by phosphorylating RB, enabling E2F transcriptional activation of S-phase genes (kasirzadeh2024targetingcdk2to pages 2-3, lashen2024theclinicopathologicalsignificance pages 1-2).

This RB–E2F placement is also captured in ovarian cancer pathway analyses: cyclin D–CDK4/6 initiates RB phosphorylation in early G1, E2F induces CCNE1 expression, and then cyclin E1–CDK2 further phosphorylates RB to complete E2F activation and commit cells to S phase (lashen2024theclinicopathologicalsignificance pages 1-2).

2.2 CCNE1 dysregulation and replication stress (conceptual linkage)

A central modern concept in CCNE1 biology is that CCNE1 amplification or cyclin E1 overexpression can accelerate G1/S progression, promoting replication stress (RS) and genomic instability; these properties create dependencies on cell-cycle checkpoints and the replication-stress response that can be therapeutically exploited (kim2025cycline1cdk2activation pages 13-14, kim2025cycline1cdk2activation pages 12-13).

3) Subcellular localization (where cyclin E1 acts)

3.1 Nuclear vs cytoplasmic localization in tumors

In a large epithelial ovarian cancer IHC study, cyclin E1 showed both nuclear and cytoplasmic localization (H-score compartment scoring). High nuclear cyclin E1 expression was associated with shorter progression-free survival (PFS) and overall survival (OS), and cyclin E1 was reported as an independent predictor of poor PFS in multivariable analysis (lashen2024theclinicopathologicalsignificance pages 7-9, lashen2024theclinicopathologicalsignificance pages 11-12).

In the same cohort, cytoplasmic cyclin E1 was frequently high (reported as 70% high vs 30% low among n=260 evaluable patients for that variable) and was also associated with worse survival metrics in analyses reported in the excerpt (lashen2024theclinicopathologicalsignificance pages 7-9).

3.2 Dynamic nucleocytoplasmic shuttling (mechanistic view)

A recent expert review notes that cyclin E (and cyclin A), together with their associated CDKs, shuttle between nucleus and cytoplasm, implying regulation at the level of nuclear import/export can modulate the functions of cyclin/CDK complexes across compartments (chen2025targetingcdk2and pages 1-3).

4) Regulation of CCNE1 abundance and activity (major mechanisms)

4.1 SCF–FBXW7-dependent ubiquitin-mediated proteolysis

Cyclin E1 levels are tightly regulated by ubiquitin-dependent degradation. FBXW7 is an F-box substrate-recognition factor for SCF (Skp1–Cullin1–F-box) E3 ubiquitin ligases that recognizes phosphodegron (Cdc4 phosphodegron) motifs, enabling proteasome-mediated turnover of substrates (boretto2024epidermalgrowthfactor pages 1-2).

Direct experimental evidence in engineered human colon organoids shows that FBXW7 mutations increase cyclin E1 (CCNE1) protein levels: “Protein levels of CCNE1
 were up-regulated in organoids carrying common missense or nonsense mutations” (boretto2024epidermalgrowthfactor pages 2-3). A 2024 molecular oncology study further contextualizes CCNE1 as a canonical FBXW7 substrate and cites classic foundational work establishing that cyclin E degradation by SCF–FBXW7 is phosphorylation-dependent (phosphodegron-dependent ubiquitination) (baxter2024cancer‐associatedfbxw7loss pages 15-16).

4.2 Structural/druggable interface biology (recent advance)

A recent chemical biology advance mapped a ligandable, cryptic allosteric pocket at the CCNE1:CDK2 interface using covalent probes and crystallography, providing a potential route to modulate cyclin E1–CDK2 function through non-ATP-site mechanisms (zhang2025anallostericcyclin pages 1-3).

5) Recent developments (prioritizing 2023–2025) and expert analysis

5.1 CCNE1 as a cancer biomarker and driver state

A 2024 ovarian cancer cohort/bioinformatics analysis reported CCNE1 amplification in 22% (67/311) of tumors in the TCGA Firehose Legacy ovarian serous cystadenocarcinoma cohort, and showed copy-number correlates with CCNE1 mRNA (Pearson r=0.53, p<0.001) (lashen2024theclinicopathologicalsignificance pages 9-11). This supports CCNE1 amplification as a frequent and clinically relevant molecular subtype in ovarian cancer.

A 2024 expert review focusing on CDK2 highlights that cyclin E upregulation (including CCNE1/CCNE2 amplifications) is associated with poor prognosis and resistance across multiple therapy classes (targeted therapy, immunotherapy, endocrine therapy, chemo/radiotherapy), reinforcing CCNE1 as a practical stratification biomarker for cell-cycle/replication-stress–targeting strategies (kasirzadeh2024targetingcdk2to pages 1-2).

5.2 Checkpoint dependency and WEE1 inhibitor sensitivity

A 2025 mechanistic/clinical study supports the model that Cyclin E1/CDK2 activation defines vulnerability to WEE1 inhibition, because CCNE1-high tumors have higher baseline replication stress and rely on checkpoint control; WEE1 inhibition exacerbates replication stress and can precipitate cell death (kim2025cycline1cdk2activation pages 12-13).

6) Current applications and real-world implementations

6.1 Biomarker assays used in practice

Recent clinical translational work notes that CCNE1 amplification is routinely reported on most next-generation sequencing platforms, and cyclin E1 IHC can serve as a feasible clinical assay to enrich for Cyclin E1/CDK2-activated tumors (kim2025cycline1cdk2activation pages 13-14).

6.2 Therapeutic strategies exploiting CCNE1-driven biology

(A) WEE1 inhibitors (clinical activity examples; biomarker-enriched):
In azenosertib clinical experience summarized in NPJ Precision Oncology, three representative responders with Cyclin E1/CDK2 activation showed week-12 tumor reductions of −57%, −42%, and −30%, including two CCNE1-amplified cases (copy numbers CN=16 and CN=17) and one CCNE1 non-amplified but Cyclin E1-high case (kim2025cycline1cdk2activation pages 12-13). A pharmacodynamic implementation detail used was ≄50% reduction in pCDK1(Y15) as a target engagement metric (kim2025cycline1cdk2activation pages 12-13).

(B) Selective CDK2 inhibitors (BLU-222; biomarker-guided development):
Preclinical and translational work on the CDK2 inhibitor BLU-222 proposes CCNE1-high tumors as CDK2-dependent and identifies combinatorial biomarker refinements involving Rb/p16 to enrich for CDK2-inhibitor sensitivity; the work cites the Phase I/II trial VELA (NCT05252416) (house2025profilingtheactivity pages 12-12).

(C) CDK2–cyclin E co-degradation (next-generation modality):
Heterobifunctional degraders that co-degrade CDK2 and cyclin E1 showed substantially stronger antiproliferative potency in CCNE1-amplified cell lines (e.g., low-nM IC50s) compared with a CCNE1-nonamplified line (micromolar-range), and were designed to improve selectivity challenges inherent to ATP-site CDK inhibition (kwiatkowski2025cdk2heterobifunctionaldegraders pages 1-1).

7) Relevant statistics and data (recent studies and trials)

Topic Key Point Quantitative/Statistical Detail Evidence Type Source URL Citation ID
Core Function & Pathway CCNE1 activates CDK2 to drive G1/S transition and S-phase entry; amplification causes replication stress and genomic instability. N/A Review / Primary Kim et al. 2025 NPJ Precis Oncol; Kasirzadeh et al. 2024 Future Oncol Link (kim2025cycline1cdk2activation pages 13-14, kasirzadeh2024targetingcdk2to pages 1-2)
Regulation (Proteolysis) Regulated by ubiquitin-mediated proteolysis via SCF-FBXW7 E3 ligase recognizing phosphodegrons; FBXW7 loss leads to accumulation. FBXW7 loss/mutation correlates with CCNE1 protein accumulation in human colon organoids. Primary Mech. Boretto et al. 2024 PNAS; Baxter et al. 2024 Mol Oncol Link (boretto2024epidermalgrowthfactor pages 2-3, baxter2024cancer‐associatedfbxw7loss pages 15-16)
Subcellular Localization Nuclear accumulation of Cyclin E1 (with CDK2) is a specific prognostic marker in ovarian cancer. High nuclear CCNE1/CDK2 linked to poor PFS (p=0.018) and OS (p=0.012). Clinical Cohort Lashen et al. 2024 Int J Mol Sci Link (lashen2024theclinicopathologicalsignificance pages 9-11)
Biomarker Statistics CCNE1 amplification frequency in high-grade serous ovarian cancer (HGSOC). 22% (67/311) of tumors in TCGA Firehose Legacy ovarian cohort. Clinical / Bioinf. Lashen et al. 2024 Int J Mol Sci Link (lashen2024theclinicopathologicalsignificance pages 9-11)
Therapeutics: WEE1i CCNE1-high tumors show vulnerability to WEE1 inhibition (azenosertib) due to high baseline replication stress. Monotherapy partial responses observed: -57%, -42%, -30% tumor reduction (waterfall plot data). Clinical Phase I Kim et al. 2025 NPJ Precis Oncol Link (kim2025cycline1cdk2activation pages 13-14, kim2025cycline1cdk2activation pages 12-13)
Therapeutics: CDK2i Selective CDK2 inhibitor BLU-222 targets CCNE1-aberrant tumors; Rb/p16 status may refine selection. VELA Trial (NCT05252416); CDK2i induces G1 arrest or S-phase slippage/collapse. Preclinical / Phase I House et al. 2025 Cancer Res Link (house2025profilingtheactivity pages 12-12)
Therapeutics: Degraders Heterobifunctional degraders co-degrade CDK2 and Cyclin E1, overcoming kinase homology selectivity issues. IC50 ~7-16 nM in CCNE1-amp lines vs ~4000 nM in non-amp; >1250-fold CDK1 sparing. Preclinical Kwiatkowski et al. 2025 Cell Chem Biol Link (kwiatkowski2025cdk2heterobifunctionaldegraders pages 1-1)

Table: Summary of key findings regarding CCNE1 function, regulation, and clinical targeting from 2024-2025 literature.

Key quantitative points from the retrieved evidence include:
- CCNE1 amplification frequency in TCGA ovarian cohort: 22% (67/311) (lashen2024theclinicopathologicalsignificance pages 9-11).
- Ovarian cancer IHC localization frequency: cytoplasmic cyclin E1 reported as 70% high vs 30% low among n=260 in one analysis subset (lashen2024theclinicopathologicalsignificance pages 7-9).
- Azenosertib clinical response examples in Cyclin E1/CDK2-activated tumors: −57%, −42%, −30% tumor reductions at week 12, with accompanying CCNE1 copy-number and Cyclin E1 H-score annotations (kim2025cycline1cdk2activation pages 12-13).
- Adavosertib (AZD1775) CCNE1-amplified basket trial design: Phase 2 (NCT03253679) enrolled 31 participants; CCNE1 amplification threshold definition (CCNE1 amplification >7 by specified NGS criteria) and ORR primary endpoint were specified; results were posted (first posted 2023-09-13) (NCT03253679 chunk 1).
- Azenosertib Cyclin E1 IHC–selected trial design: DENALI/GOG-3066 (NCT05128825) planned enrollment 170; Part 2 requires Cyclin E1-positive by central IHC and uses ORR per RECIST v1.1 as primary endpoint (NCT05128825 chunk 1).
- BLU-222 first-in-human trial design: VELA (NCT05252416) enrollment listed as 50; includes a cohort for platinum-resistant/refractory ovarian cancer with CCNE1 amplification; trial marked terminated before Phase 2 for reasons not due to safety (NCT05252416 chunk 1).

8) Figure/Table evidence (visual)

Cropped figure/table panels from Kim et al. (2025) show representative azenosertib clinical response cases and biomarker context (Cyclin E1 IHC and CCNE1 copy number), supporting the reported −57/−42/−30% tumor reductions (kim2025cycline1cdk2activation media 5f32e8dd, kim2025cycline1cdk2activation media cd829d1a, kim2025cycline1cdk2activation media 43760d10).

9) Summary (functional annotation)

CCNE1 (cyclin E1; UniProt P24864) is best annotated as a CDK2-activating cyclin that enforces late-G1 progression and G1/S commitment via the RB–E2F axis, with activity and abundance tuned by SCF–FBXW7 phosphodegron-dependent ubiquitin-mediated degradation. In cancer, CCNE1 amplification/overexpression is a frequent genomic state (e.g., ~22% in TCGA ovarian cohort) associated with dysregulated cell-cycle entry and replication stress, creating translational vulnerabilities to checkpoint and cell-cycle therapeutics (WEE1 inhibitors, emerging CDK2 inhibitors, and CDK2/cyclin E degraders) increasingly implemented via NGS-based amplification calls and/or Cyclin E1 IHC selection (lashen2024theclinicopathologicalsignificance pages 1-2, boretto2024epidermalgrowthfactor pages 2-3, lashen2024theclinicopathologicalsignificance pages 9-11, kim2025cycline1cdk2activation pages 12-13).

References

  1. (zhang2025anallostericcyclin pages 1-3): Yuanjin Zhang, Zhonglin Liu, Marscha Hirschi, Oleg Brodsky, Eric Johnson, Sang Joon Won, Asako Nagata, Divya Bezwada, Matthew D. Petroski, Jaimeen D. Majmudar, Sherry Niessen, Todd VanArsdale, Adam M. Gilbert, Matthew M. Hayward, Al E. Stewart, Andrew R. Nager, Bruno Melillo, and Benjamin F. Cravatt. An allosteric cyclin e-cdk2 site mapped by paralog hopping with covalent probes. Nature chemical biology, 21:420-431, Sep 2025. URL: https://doi.org/10.1038/s41589-024-01738-7, doi:10.1038/s41589-024-01738-7. This article has 13 citations and is from a highest quality peer-reviewed journal.

  2. (kasirzadeh2024targetingcdk2to pages 2-3): Sara Kasirzadeh, Jimma Likisa Lenjisa, and Shudong Wang. Targeting cdk2 to combat drug resistance in cancer therapy. Future oncology, 20:1-17, Oct 2024. URL: https://doi.org/10.1080/14796694.2024.2416382, doi:10.1080/14796694.2024.2416382. This article has 13 citations and is from a peer-reviewed journal.

  3. (lashen2024theclinicopathologicalsignificance pages 1-2): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1–cyclin-dependent kinase (cdk2/4/6)–retinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.

  4. (kim2025cycline1cdk2activation pages 13-14): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.

  5. (kim2025cycline1cdk2activation pages 12-13): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.

  6. (lashen2024theclinicopathologicalsignificance pages 7-9): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1–cyclin-dependent kinase (cdk2/4/6)–retinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.

  7. (lashen2024theclinicopathologicalsignificance pages 11-12): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1–cyclin-dependent kinase (cdk2/4/6)–retinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.

  8. (chen2025targetingcdk2and pages 1-3): Mei-Kuang Chen, Linjie Luo, Nicole Massoumi, and Khandan Keyomarsi. Targeting cdk2 and other novel cell cycle targets for breast cancer therapy. Jul 2025. URL: https://doi.org/10.1080/14728222.2025.2537412, doi:10.1080/14728222.2025.2537412. This article has 3 citations and is from a peer-reviewed journal.

  9. (boretto2024epidermalgrowthfactor pages 1-2): Matteo Boretto, Maarten H. Geurts, Shashank Gandhi, Ziliang Ma, Nadzeya Staliarova, Martina Celotti, Sangho Lim, Gui-Wei He, Rosemary Millen, Else Driehuis, Harry Begthel, Lidwien Smabers, Jeanine Roodhart, Johan van Es, Wei Wu, and Hans Clevers. Epidermal growth factor receptor (egfr) is a target of the tumor-suppressor e3 ligase fbxw7. Proceedings of the National Academy of Sciences of the United States of America, Mar 2024. URL: https://doi.org/10.1073/pnas.2309902121, doi:10.1073/pnas.2309902121. This article has 26 citations and is from a highest quality peer-reviewed journal.

  10. (boretto2024epidermalgrowthfactor pages 2-3): Matteo Boretto, Maarten H. Geurts, Shashank Gandhi, Ziliang Ma, Nadzeya Staliarova, Martina Celotti, Sangho Lim, Gui-Wei He, Rosemary Millen, Else Driehuis, Harry Begthel, Lidwien Smabers, Jeanine Roodhart, Johan van Es, Wei Wu, and Hans Clevers. Epidermal growth factor receptor (egfr) is a target of the tumor-suppressor e3 ligase fbxw7. Proceedings of the National Academy of Sciences of the United States of America, Mar 2024. URL: https://doi.org/10.1073/pnas.2309902121, doi:10.1073/pnas.2309902121. This article has 26 citations and is from a highest quality peer-reviewed journal.

  11. (baxter2024cancer‐associatedfbxw7loss pages 15-16): Joseph S. Baxter, Rachel Brough, Dragomir B. Krastev, Feifei Song, Sandhya Sridhar, Aditi Gulati, John Alexander, Theodoros I. Roumeliotis, Zuza Kozik, Jyoti S. Choudhary, Syed Haider, Stephen J. Pettitt, Andrew N. J. Tutt, and Christopher J. Lord. Cancer‐associated fbxw7 loss is synthetic lethal with pharmacological targeting of cdc7. Molecular Oncology, 18:369-385, Oct 2024. URL: https://doi.org/10.1002/1878-0261.13537, doi:10.1002/1878-0261.13537. This article has 6 citations and is from a peer-reviewed journal.

  12. (lashen2024theclinicopathologicalsignificance pages 9-11): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1–cyclin-dependent kinase (cdk2/4/6)–retinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.

  13. (kasirzadeh2024targetingcdk2to pages 1-2): Sara Kasirzadeh, Jimma Likisa Lenjisa, and Shudong Wang. Targeting cdk2 to combat drug resistance in cancer therapy. Future oncology, 20:1-17, Oct 2024. URL: https://doi.org/10.1080/14796694.2024.2416382, doi:10.1080/14796694.2024.2416382. This article has 13 citations and is from a peer-reviewed journal.

  14. (house2025profilingtheactivity pages 12-12): Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, and Kerrie L. Faia. Profiling the activity of the potent and highly selective cdk2 inhibitor blu-222 reveals determinants of response in ccne1 -aberrant ovarian and endometrial tumors. Cancer Research, 85:1297-1309, Feb 2025. URL: https://doi.org/10.1158/0008-5472.can-24-2360, doi:10.1158/0008-5472.can-24-2360. This article has 17 citations and is from a highest quality peer-reviewed journal.

  15. (kwiatkowski2025cdk2heterobifunctionaldegraders pages 1-1): Nicholas Kwiatkowski, Tong Liang, Zhe Sha, Philip N. Collier, Annan Yang, Murugappan Sathappa, Atanu Paul, Lijing Su, Xiaozhang Zheng, Robert Aversa, Kunhua Li, Revonda Mehovic, Christina Kolodzy, Susanne B. Breitkopf, Dapeng Chen, Charles L. Howarth, Karen Yuan, Hakryul Jo, Joseph D. Growney, Matthew Weiss, and Juliet Williams. Cdk2 heterobifunctional degraders co-degrade cdk2 and cyclin e resulting in efficacy in ccne1-amplified and overexpressed cancers. Cell chemical biology, 32 4:556-569.e24, Apr 2025. URL: https://doi.org/10.1016/j.chembiol.2025.03.006, doi:10.1016/j.chembiol.2025.03.006. This article has 9 citations and is from a domain leading peer-reviewed journal.

  16. (NCT03253679 chunk 1): AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification. National Cancer Institute (NCI). 2019. ClinicalTrials.gov Identifier: NCT03253679

  17. (NCT05128825 chunk 1): A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer. K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. 2022. ClinicalTrials.gov Identifier: NCT05128825

  18. (NCT05252416 chunk 1): (VELA) Study of BLU-222 in Advanced Solid Tumors. Blueprint Medicines Corporation. 2022. ClinicalTrials.gov Identifier: NCT05252416

  19. (kim2025cycline1cdk2activation media 5f32e8dd): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.

  20. (kim2025cycline1cdk2activation media cd829d1a): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.

  21. (kim2025cycline1cdk2activation media 43760d10): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.

Citations

  1. zhang2025anallostericcyclin pages 1-3
  2. lashen2024theclinicopathologicalsignificance pages 1-2
  3. lashen2024theclinicopathologicalsignificance pages 7-9
  4. boretto2024epidermalgrowthfactor pages 1-2
  5. boretto2024epidermalgrowthfactor pages 2-3
  6. lashen2024theclinicopathologicalsignificance pages 9-11
  7. house2025profilingtheactivity pages 12-12
  8. lashen2024theclinicopathologicalsignificance pages 11-12
  9. Link
  10. https://doi.org/10.1038/s41698-024-00787-4
  11. https://doi.org/10.1073/pnas.2309902121
  12. https://doi.org/10.3390/ijms25074060
  13. https://doi.org/10.1158/0008-5472.can-24-2360
  14. https://doi.org/10.1016/j.chembiol.2025.03.006
  15. https://doi.org/10.1038/s41589-024-01738-7,
  16. https://doi.org/10.1080/14796694.2024.2416382,
  17. https://doi.org/10.3390/ijms25074060,
  18. https://doi.org/10.1038/s41698-024-00787-4,
  19. https://doi.org/10.1080/14728222.2025.2537412,
  20. https://doi.org/10.1073/pnas.2309902121,
  21. https://doi.org/10.1002/1878-0261.13537,
  22. https://doi.org/10.1158/0008-5472.can-24-2360,
  23. https://doi.org/10.1016/j.chembiol.2025.03.006,

📄 View Raw YAML

id: P24864
gene_symbol: CCNE1
product_type: PROTEIN
status: IN_PROGRESS
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  CCNE1 encodes cyclin E1, a regulatory subunit of the cyclin-dependent kinase CDK2.
  Cyclin E1 binds and activates CDK2, driving phosphorylation of key substrates such
  as RB1 to promote the G1/S transition of the cell cycle and commitment to S-phase
  entry. Cyclin E1 itself has no catalytic activity; its role is to confer substrate
  specificity and temporal activation on CDK2. The protein is predominantly nuclear
  and its abundance is tightly regulated by SCF-FBXW7-dependent ubiquitin-mediated
  proteolysis, triggered by phosphodegron motifs phosphorylated by CDK2 and GSK3.
  CCNE1 amplification and overexpression are frequent in cancers, particularly
  high-grade serous ovarian cancer (~22% of TCGA cases), where they drive replication
  stress and genomic instability.
existing_annotations:
  - term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Core function. Cyclin E1 is the canonical regulator of G1/S transition via
        CDK2 activation. Extensively supported by phylogenetic inference (IBA) and
        all literature.
      action: ACCEPT
      reason: >-
        G1/S transition is the defining biological process for cyclin E1. The deep
        research (CCNE1-deep-research-falcon.md) confirms "Cyclin E1 is a non-enzymatic
        regulatory subunit whose primary molecular function is to bind and activate
        CDK2, thereby promoting late G1 progression and G1/S transition"
        (kasirzadeh2024targetingcdk2to). IBA annotations for such core functions
        are typically well-reviewed.
      supported_by:
        - reference_id: PMID:15838514
          supporting_text: >-
            Cyclin E-Cdk2 has long been considered an essential and master regulator of
            progression through G1 phase of the cell cycle
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Cyclin E1 is a nuclear protein as established by multiple lines of evidence
        including the UniProt record which states "Nucleus" with experimental evidence
        from PMID:7739542.
      action: ACCEPT
      reason: >-
        Nuclear localization of cyclin E1 is well established. UniProt states
        "SUBCELLULAR LOCATION: Nucleus" with experimental evidence. IBA annotation
        is consistent.
      supported_by:
        - reference_id: PMID:19942931
          supporting_text: >-
            Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S
            phase cell cycle regulator
  - term:
      id: GO:0005737
      label: cytoplasm
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Cyclin E1 is also found in the cytoplasm. IHC studies show both nuclear and
        cytoplasmic localization, and the deep research notes nucleocytoplasmic
        shuttling.
      action: ACCEPT
      reason: >-
        Cytoplasmic localization is supported by IHC evidence showing "cytoplasmic
        cyclin E1 was frequently high (70% high vs 30% low)" in ovarian cancer
        (lashen2024theclinicopathologicalsignificance). Cyclin E and CDK2 are
        known to shuttle between nucleus and cytoplasm
        (chen2025targetingcdk2and). IBA annotation is consistent.
  - term:
      id: GO:0016538
      label: cyclin-dependent protein serine/threonine kinase regulator activity
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Core molecular function of cyclin E1. It is a non-enzymatic regulatory subunit
        that binds and activates CDK2, a cyclin-dependent serine/threonine kinase.
      action: ACCEPT
      reason: >-
        This is the defining molecular function of cyclin E1. It does not have kinase
        activity itself but activates CDK2. PMID:8207080 confirms "Cyclin E is a
        regulatory subunit of the cdc2-related protein kinase cdk2." The IBA
        annotation is at the right level of specificity.
      supported_by:
        - reference_id: PMID:8207080
          supporting_text: >-
            Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
            which is activated shortly before S-phase entry, thus defining it as a G1
            cyclin
  - term:
      id: GO:0097134
      label: cyclin E1-CDK2 complex
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Cyclin E1 is a defining component of the cyclin E1-CDK2 complex. Crystal
        structure of the complex has been solved (PDB:1W98, PMID:15660127).
      action: ACCEPT
      reason: >-
        UniProt states "Interacts with CDK2 protein kinase to form a serine/threonine
        kinase holoenzyme complex." Multiple crystal structures confirm this
        (PDB:1W98). ComplexPortal entry CPX-2015 explicitly defines the
        Cyclin E1-CDK2 complex.
  - term:
      id: GO:0005815
      label: microtubule organizing center
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Cyclin E-CDK2 is known to play a role in centrosome duplication, and
        localization to centrosomes (microtubule organizing centers) has been reported
        in the literature for cyclin E in model organisms. The IBA annotation reflects
        phylogenetic inference from orthologs.
      action: ACCEPT
      reason: >-
        Cyclin E-CDK2 activity is required for centrosome duplication, and cyclin E
        has been shown to localize to centrosomes. This is supported by the broader
        cell cycle biology literature and is phylogenetically conserved (IBA).
  - term:
      id: GO:1900087
      label: positive regulation of G1/S transition of mitotic cell cycle
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Cyclin E1 positively regulates G1/S transition by activating CDK2, which
        phosphorylates RB1 to release E2F transcription factors for S-phase gene
        expression.
      action: ACCEPT
      reason: >-
        This is a core function. The deep research confirms "CDK2-cyclin E activity
        promotes S-phase entry in large part by phosphorylating RB, enabling E2F
        transcriptional activation" (kasirzadeh2024targetingcdk2to). The IBA
        annotation is at the right level of specificity.
      supported_by:
        - reference_id: PMID:15838514
          supporting_text: >-
            Cyclin E-Cdk2 has long been considered an essential and master regulator of
            progression through G1 phase of the cell cycle
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        IEA annotation for nuclear localization, consistent with the IBA and IDA
        annotations for the same term.
      action: ACCEPT
      reason: >-
        Redundant with IBA and IDA annotations but not wrong. Nuclear localization
        is well established for cyclin E1.
  - term:
      id: GO:0051301
      label: cell division
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: >-
        IEA annotation from UniProt keyword mapping. Cell division is a broad term
        that encompasses the G1/S transition role of cyclin E1.
      action: ACCEPT
      reason: >-
        While broader than the more specific G1/S transition annotations, this IEA
        is not wrong. Cyclin E1 is clearly involved in cell division. The UniProt
        record includes "Cell cycle; Cell division" as keywords.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:10330164
    review:
      summary: >-
        Interaction with p300 coactivator. PMID:10330164 shows cyclin E-Cdk2 binds
        to the COOH-terminal region of p300, though this is described as a complex
        interaction (cyclin E-Cdk2 rather than cyclin E alone).
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        The term "protein binding" is uninformative. The actual finding is a specific
        interaction of cyclin E-Cdk2 complex with the p300 coactivator. However,
        the GO guidelines discourage generic protein binding annotations.
      supported_by:
        - reference_id: PMID:10330164
          supporting_text: >-
            the COOH-terminal region of p300 binds to cyclin E-cyclin-dependent kinase 2
            (cyclin E-Cdk2) and TFIIB
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:11533444
    review:
      summary: >-
        Interaction with FBXW7 (SCFFbw7) for phosphorylation-dependent ubiquitination.
        This is a well-characterized substrate-E3 ligase interaction.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        The term "protein binding" is uninformative. The actual interaction is between
        cyclin E and FBXW7 as part of SCF-mediated ubiquitination. This is better
        captured by other annotations related to cyclin E degradation.
      supported_by:
        - reference_id: PMID:11533444
          supporting_text: >-
            Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin
            ligase
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:16223725
    review:
      summary: >-
        Interaction with PIN1 prolyl isomerase. PIN1 regulates cyclin E stability.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual finding is PIN1
        regulation of cyclin E stability.
      supported_by:
        - reference_id: PMID:16223725
          supporting_text: >-
            The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts
            to genomic instability
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:16431923
    review:
      summary: >-
        Interaction with SARS-CoV nucleocapsid protein, which inhibits cyclin-CDK
        activity. This is a viral pathogen interaction, not a core function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The interaction is with a viral
        protein (SARS-CoV nucleocapsid) and represents pathogen interference with
        cell cycle, not a core function of cyclin E1.
      supported_by:
        - reference_id: PMID:16431923
          supporting_text: >-
            The nucleocapsid protein of severe acute respiratory syndrome-coronavirus
            inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks
            S phase progression in mammalian cells
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:16504183
    review:
      summary: >-
        Interaction with FOXM1c transcription factor, regulated by Cyclin E/CDK2.
        UniProt lists FOXM1 as an interaction partner.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual finding is regulation
        of FOXM1c by cyclin E/CDK2 complex phosphorylation.
      supported_by:
        - reference_id: PMID:16504183
          supporting_text: >-
            Regulation of the transcription factor FOXM1c by Cyclin E/CDK2
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:16721056
    review:
      summary: >-
        Interaction with AKAP95 (A-kinase anchoring protein). G1/S cyclins interact
        with PKA regulatory subunit via AKAP95.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. UniProt lists AKAP8 as an
        interaction partner.
      supported_by:
        - reference_id: PMID:16721056
          supporting_text: >-
            G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring
            protein, AKAP95
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:16765349
    review:
      summary: >-
        Interaction with p21 (CDKN1A) in retinoid-induced apoptosis. p21 is a
        well-known CDK inhibitor that forms complexes with cyclin E/CDK2.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The cyclin E-CDK2-p21 interaction
        is a core regulatory mechanism but should be annotated more specifically.
        UniProt lists CDKN1A with 11 experiments.
      supported_by:
        - reference_id: PMID:16765349
          supporting_text: >-
            Increased p21 expression and complex formation with cyclin E/CDK2 in
            retinoid-induced pre-B lymphoma cell apoptosis
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:17254966
    review:
      summary: >-
        Interaction with p27Kip1 (CDKN1B). This is a key CDK inhibitor that
        regulates cyclin E-CDK2 activity.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The cyclin E-CDK2-p27 interaction
        is well characterized. UniProt lists CDKN1B with 12 experiments.
      supported_by:
        - reference_id: PMID:17254966
          supporting_text: >-
            Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by
            oncogenic tyrosine kinases
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:17254967
    review:
      summary: >-
        Another study on p27-cyclin E-Cdk2 interaction, showing Src-dependent
        phosphorylation of p27 regulates inhibition of cyclin E-Cdk2.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. This is the same well-characterized
        p27-cyclin E-CDK2 interaction.
      supported_by:
        - reference_id: PMID:17254967
          supporting_text: >-
            p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:17525332
    review:
      summary: >-
        Large-scale ATM/ATR substrate analysis. This is a high-throughput study
        identifying proteins in DNA damage response networks, not a focused study
        on cyclin E function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a high-throughput study. Does not provide
        specific information about cyclin E1 function.
      supported_by:
        - reference_id: PMID:17525332
          supporting_text: >-
            ATM and ATR substrate analysis reveals extensive protein networks responsive
            to DNA damage
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:19470470
    review:
      summary: >-
        Study on RSK1-p27Kip1 phosphorylation. Cyclin E is mentioned as a binding
        partner of p27 but the study focuses on RSK1 function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The study focuses on RSK1
        regulation of p27, with cyclin E as a known interactor.
      supported_by:
        - reference_id: PMID:19470470
          supporting_text: >-
            RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and
            increase cell motility
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21092281
    review:
      summary: >-
        HTLV-I p30 decreases cyclin E-CDK2 interactions. This is a viral
        interference study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. This describes viral pathogen
        interference with cyclin E-CDK2, not a core function.
      supported_by:
        - reference_id: PMID:21092281
          supporting_text: >-
            HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin
            E-CDK2 interactions and delays cell cycle progression
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21952639
    review:
      summary: >-
        Interaction with UHRF2 (NIRF), which ubiquitinates cyclin E1. UniProt
        confirms this interaction with 4 experiments.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual interaction is a
        substrate-E3 ligase relationship where UHRF2 ubiquitinates cyclin E1.
        UniProt states "Interacts directly with UHRF2; the interaction ubiquitinates
        CCNE1."
      supported_by:
        - reference_id: PMID:21952639
          supporting_text: >-
            the ubiquitin ligase NIRF (also known as UHRF2), which induces G1 arrest,
            interacts with multiple cell cycle proteins including cyclins (A2, B1, D1
            and E1), p53 and pRB, and ubiquitinates cyclins D1 and E1
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21988832
    review:
      summary: >-
        High-throughput protein interaction study of the human liver. Not a focused
        study on cyclin E1 function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a large-scale interactome study. Uninformative
        for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:21988832
          supporting_text: >-
            Toward an understanding of the protein interaction network of the human liver
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:23455922
    review:
      summary: >-
        Large-scale AP-MS reproducibility study. Not a focused study on cyclin E1.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a high-throughput methods study. Uninformative
        for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:23455922
          supporting_text: >-
            Interlaboratory reproducibility of large-scale human protein-complex analysis
            by standardized AP-MS
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:23602568
    review:
      summary: >-
        CMGC kinase group interactome study. CDK2 is a CMGC kinase, so cyclin E1
        would be identified as an interactor.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a kinase interactome study. The cyclin E-CDK2
        interaction is already well captured by more specific annotations.
      supported_by:
        - reference_id: PMID:23602568
          supporting_text: >-
            The protein interaction landscape of the human CMGC kinase group
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:23853094
    review:
      summary: >-
        Foxp3 stability regulation by CDK2. The study shows CDK2 phosphorylates
        Foxp3, with cyclin E as the activating partner.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual biology is CDK2
        phosphorylation of Foxp3, where cyclin E1 is the activating cyclin partner.
      supported_by:
        - reference_id: PMID:23853094
          supporting_text: >-
            Foxp3 protein stability is regulated by cyclin-dependent kinase 2
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:24358021
    review:
      summary: >-
        SCML2 binding to CDK/CYCLIN/p21 complexes. Cyclin E is one of the cyclins
        in such complexes.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The study describes SCML2
        modulating CDK/cyclin/p21 complexes, with cyclin E as one component.
      supported_by:
        - reference_id: PMID:24358021
          supporting_text: >-
            Polycomb protein SCML2 regulates the cell cycle by binding and modulating
            CDK/CYCLIN/p21 complexes
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:25241761
    review:
      summary: >-
        In situ proximity ligation assay (PLA) study for profiling endogenous
        protein-protein interactions.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a methods-focused study. Uninformative for
        cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:25241761
          supporting_text: >-
            Using an in situ proximity ligation assay to systematically profile
            endogenous protein-protein interactions in a pathway network
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:25852190
    review:
      summary: >-
        Kinase network analysis in TRAIL-induced apoptosis. High-throughput study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a high-throughput network analysis study.
        Uninformative for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:25852190
          supporting_text: >-
            Integrative analysis of kinase networks in TRAIL-induced apoptosis provides
            a source of potential targets for combination therapy
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:28514442
    review:
      summary: >-
        Large-scale human interactome architecture study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a large-scale interactome study. Uninformative
        for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:28514442
          supporting_text: >-
            Architecture of the human interactome defines protein communities and disease
            networks
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:32296183
    review:
      summary: >-
        Binary protein interactome reference map.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a large-scale interactome mapping study.
        Uninformative for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:32296183
          supporting_text: >-
            A reference map of the human binary protein interactome
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:33961781
    review:
      summary: >-
        Dual proteome-scale interactome study showing cell-specific remodeling.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a large-scale interactome study. Uninformative
        for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:33961781
          supporting_text: >-
            Dual proteome-scale networks reveal cell-specific remodeling of the human
            interactome
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:34591612
    review:
      summary: >-
        Protein interaction landscape of breast cancer.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a tissue-specific interactome study.
        Uninformative for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:34591612
          supporting_text: >-
            A protein interaction landscape of breast cancer
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:35271311
    review:
      summary: >-
        OpenCell endogenous tagging and cartography study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a large-scale cellular organization study.
        Uninformative for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:35271311
          supporting_text: >-
            OpenCell: Endogenous tagging for the cartography of human cellular
            organization
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:35512704
    review:
      summary: >-
        Mutation-directed neo-protein-protein interactions in cancer.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a high-throughput cancer study. Uninformative
        for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:35512704
          supporting_text: >-
            Systematic discovery of mutation-directed neo-protein-protein interactions
            in cancer
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:40205054
    review:
      summary: >-
        Multimodal cell maps study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding from a large-scale cellular mapping study.
        Uninformative for cyclin E1 functional annotation.
      supported_by:
        - reference_id: PMID:40205054
          supporting_text: >-
            Multimodal cell maps as a foundation for structural and functional genomics
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:8553588
    review:
      summary: >-
        HPV E7 oncoproteins bind cyclin E in a complex with CDK2 and p107. This
        represents viral oncogene interaction with the cyclin E-CDK2 complex.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual finding involves viral
        E7 oncoprotein binding to cyclin E-CDK2-p107 complexes, which is a pathogen
        interaction, not a core function.
      supported_by:
        - reference_id: PMID:8553588
          supporting_text: >-
            Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a
            complex with cdk2 and p107
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:8756624
    review:
      summary: >-
        Cyclin-binding motifs essential for p21CIP1 function. This demonstrates the
        p21-cyclin E interaction is functionally important.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The study reveals specific
        cyclin-binding motifs in p21, but the annotation should be more specific
        than "protein binding."
      supported_by:
        - reference_id: PMID:8756624
          supporting_text: >-
            Cyclin-binding motifs are essential for the function of p21CIP1
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:9840943
    review:
      summary: >-
        Cyclin E2 discovery paper that also characterizes cyclin E1 interactions with
        CDK2 and CDK3.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The CDK2 interaction is already
        captured by the more specific cyclin E1-CDK2 complex annotation
        (GO:0097134).
      supported_by:
        - reference_id: PMID:9840943
          supporting_text: >-
            Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3,
            is induced by viral oncoproteins
  - term:
      id: GO:0000307
      label: cyclin-dependent protein kinase holoenzyme complex
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        IEA annotation for CDK holoenzyme complex membership. This is a more general
        parent of cyclin E1-CDK2 complex (GO:0097134).
      action: ACCEPT
      reason: >-
        While more general than GO:0097134 (cyclin E1-CDK2 complex), this IEA
        annotation is not wrong. Cyclin E1 is indeed a component of a
        cyclin-dependent protein kinase holoenzyme complex (the CDK2 holoenzyme).
        It is acceptable for IEA annotations to be broader.
  - term:
      id: GO:0016301
      label: kinase activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        IEA annotation attributing kinase activity to cyclin E1. However, cyclin E1
        is NOT a kinase; it is a regulatory subunit that activates CDK2.
      action: REMOVE
      reason: >-
        Cyclin E1 does not have kinase activity itself. It is a non-enzymatic
        regulatory subunit that binds and activates CDK2. PMID:8207080 confirms
        "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2."
        The kinase activity belongs to CDK2, not cyclin E1. The correct MF annotation
        is GO:0016538 (cyclin-dependent protein serine/threonine kinase regulator
        activity), which is already annotated. This IEA annotation is incorrect and
        should be removed.
      supported_by:
        - reference_id: PMID:8207080
          supporting_text: >-
            Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
            which is activated shortly before S-phase entry
  - term:
      id: GO:0016538
      label: cyclin-dependent protein serine/threonine kinase regulator activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        IEA annotation consistent with the IBA annotation for the same term.
        This is the correct molecular function for cyclin E1.
      action: ACCEPT
      reason: >-
        Consistent with the IBA annotation. This is the defining molecular function
        of cyclin E1 as a CDK2 regulatory subunit.
  - term:
      id: GO:0019901
      label: protein kinase binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        IEA annotation for protein kinase binding. Cyclin E1 does bind CDK2 (a
        protein kinase), so this is technically correct but vague.
      action: ACCEPT
      reason: >-
        Cyclin E1 binds CDK2, which is a protein kinase. UniProt states "Interacts
        with CDK2 protein kinase to form a serine/threonine kinase holoenzyme
        complex" (PMID:15660127). While more informative terms exist (GO:0016538),
        this IEA annotation is not incorrect and can be retained as a broader term.
  - term:
      id: GO:0097134
      label: cyclin E1-CDK2 complex
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        IEA annotation consistent with IBA annotation for the same term.
      action: ACCEPT
      reason: >-
        Consistent with the IBA annotation. Cyclin E1 is a defining component of
        the cyclin E1-CDK2 complex (ComplexPortal CPX-2015).
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: IDA
    original_reference_id: GO_REF:0000052
    review:
      summary: >-
        IDA annotation from HPA immunofluorescence data showing nucleoplasmic
        localization.
      action: ACCEPT
      reason: >-
        Nucleoplasmic localization is consistent with cyclin E1 being a nuclear
        protein that functions in cell cycle regulation within the nucleus.
        This is supported by multiple lines of evidence.
  - term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
    evidence_type: NAS
    original_reference_id: PMID:15838514
    review:
      summary: >-
        NAS annotation from a review article on cyclin E in normal and neoplastic
        cell cycles. Confirms the core function of cyclin E1 in G1/S transition.
      action: ACCEPT
      reason: >-
        Core function annotation supported by review literature. PMID:15838514
        states "Cyclin E-Cdk2 has long been considered an essential and master
        regulator of progression through G1 phase of the cell cycle."
      supported_by:
        - reference_id: PMID:15838514
          supporting_text: >-
            Cyclin E-Cdk2 has long been considered an essential and master regulator of
            progression through G1 phase of the cell cycle
  - term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
    evidence_type: IMP
    original_reference_id: PMID:23083510
    review:
      summary: >-
        IMP annotation from a study showing miR-16 targets cyclin E1 to inhibit
        mesenchymal stem cell proliferation and induce cell cycle arrest. Cyclin E1
        knockdown/downregulation caused cell cycle arrest, supporting its role in
        G1/S transition.
      action: ACCEPT
      reason: >-
        The study shows that miR-16 targets cyclin E1, and over-expression of
        miR-16 "inhibited the proliferation and migration of decidua-derived
        mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1"
        (PMID:23083510). This supports cyclin E1 involvement in G1/S transition.
      supported_by:
        - reference_id: PMID:23083510
          supporting_text: >-
            over-expressed miR-16 inhibited the proliferation and migration of
            decidua-derived mesenchymal stem cells and induced cell-cycle arrest by
            targeting cyclin E1
  - term:
      id: GO:1902462
      label: positive regulation of mesenchymal stem cell proliferation
    evidence_type: IMP
    original_reference_id: PMID:23083510
    review:
      summary: >-
        IMP annotation from miR-16 study in pre-eclampsia. While cyclin E1 promotes
        proliferation of mesenchymal stem cells (shown by miR-16 targeting), this is
        a very specific biological context (decidual MSCs in pre-eclampsia) rather
        than a core function.
      action: KEEP_AS_NON_CORE
      reason: >-
        Cyclin E1 does promote proliferation in MSCs as shown by the miR-16 study,
        but this is a pleiotropic effect of its general cell cycle role in a
        specific cell type context, not a core evolved function. The annotation is
        technically supported but represents a context-specific manifestation.
      supported_by:
        - reference_id: PMID:23083510
          supporting_text: >-
            over-expressed miR-16 inhibited the proliferation and migration of
            decidua-derived mesenchymal stem cells and induced cell-cycle arrest by
            targeting cyclin E1
  - term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
    evidence_type: IMP
    original_reference_id: PMID:25732226
    review:
      summary: >-
        IMP annotation from study showing miR-30c-2-3p targets CCNE1 in breast
        cancer cells. Inhibition of CCNE1 phenocopied effects on cell proliferation.
      action: ACCEPT
      reason: >-
        The study confirms that CCNE1 downregulation affects cell cycle progression.
        "inhibition of CCNE1 phenocopied the effects on cell proliferation"
        (PMID:25732226). Supports G1/S transition role.
      supported_by:
        - reference_id: PMID:25732226
          supporting_text: >-
            inhibition of CCNE1 phenocopied the effects on cell proliferation
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21540187
    review:
      summary: >-
        Interaction with INCA1 (inhibitor of CDK interacting with cyclin A1).
        UniProt confirms "Interacts with INCA1" (PMID:21540187).
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual interaction is between
        cyclin E1 and INCA1, a CDK inhibitor. UniProt confirms this interaction.
      supported_by:
        - reference_id: PMID:21540187
          supporting_text: >-
            we identified INCA1 as an interaction partner and a substrate of cyclin A1
            in complex with CDK2
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:19942931
    review:
      summary: >-
        Nuclear localization of cyclin E1 observed in trophoblast cells. The study
        shows Mtd-L colocalizes with cyclin E1 in the nuclear compartment.
      action: ACCEPT
      reason: >-
        Nuclear localization confirmed by immunofluorescence in proliferating
        trophoblast cells. "Mtd expression in proliferating cells colocalized with
        cyclin E1, a G(1)/S phase cell cycle regulator" (PMID:19942931). Consistent
        with UniProt annotation.
      supported_by:
        - reference_id: PMID:19942931
          supporting_text: >-
            Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S
            phase cell cycle regulator
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:17434132
    review:
      summary: >-
        Structural study of Fbw7-Skp1-cyclin E complex. Demonstrates the molecular
        basis for cyclin E recognition by SCF-FBXW7 for ubiquitin-mediated
        degradation. This is a well-characterized interaction.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual finding is the structural
        basis for FBXW7 recognition of phosphorylated cyclin E degrons. This
        interaction is critical for cyclin E turnover but "protein binding" does not
        capture the functional significance.
      supported_by:
        - reference_id: PMID:17434132
          supporting_text: >-
            Cyclin E degradation is triggered by multisite phosphorylation, which
            induces binding to the SCF(Fbw7) ubiquitin ligase complex
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-187520
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasmic localization, from the Cyclin
        E/A:Cdk2-mediated phosphorylation of p27/p21 reaction.
      action: ACCEPT
      reason: >-
        Cyclin E-CDK2 mediates phosphorylation of p27/p21 in the nucleoplasm as
        part of the Skp2-mediated degradation pathway. Consistent with nuclear
        function.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-187552
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from binding of phospho-p27/p21
        to SCF(Skp2):Cks1 complex.
      action: ACCEPT
      reason: >-
        Consistent with established nucleoplasmic function of cyclin E-CDK2 complex.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-187574
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from degradation of ubiquitinated
        p27/p21 by 26S proteasome.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization during cell cycle regulation.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-187575
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from ubiquitination of
        phospho-p27/p21.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization during cell cycle regulation.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-188350
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from CAK-mediated phosphorylation
        of Cyclin E:Cdk2.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization during cell cycle regulation.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-188386
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from association of Rb with
        Cyclin E:Cdk2 complexes.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization for RB1 phosphorylation by
        cyclin E-CDK2.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-188390
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from Cyclin E:CDK2-mediated
        phosphorylation of RB1.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization for the core function of
        RB1 phosphorylation.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-69005
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from Cdc6 phosphorylation by CDK.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization. Cdc6 phosphorylation by
        cyclin E-CDK2 is part of DNA replication licensing.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-69195
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from phosphorylation of Cyclin
        E:CDK2 complexes by WEE1.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization during cell cycle checkpoint
        regulation.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-69199
    review:
      summary: >-
        Reactome TAS annotation for nucleoplasm, from dephosphorylation of Cyclin
        E:Cdk2 complexes by Cdc25A.
      action: ACCEPT
      reason: >-
        Consistent with nucleoplasmic localization during cell cycle regulation.
  - term:
      id: GO:0005829
      label: cytosol
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-157906
    review:
      summary: >-
        Reactome TAS annotation for cytosol, from translocation of Cyclin E:Cdk2
        complex to the nucleus. Cyclin E-CDK2 is present in the cytosol before
        nuclear translocation.
      action: ACCEPT
      reason: >-
        Cyclin E-CDK2 complexes form in the cytosol before translocation to the
        nucleus. The Reactome reaction R-HSA-157906 specifically describes this
        translocation, implying cytosolic presence.
  - term:
      id: GO:0005829
      label: cytosol
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-69191
    review:
      summary: >-
        Reactome TAS annotation for cytosol, from formation of Cyclin E:Cdk2
        complexes.
      action: ACCEPT
      reason: >-
        Cyclin E-CDK2 complex formation occurs in the cytosol. Consistent with
        known biology of cyclin-CDK complex assembly.
  - term:
      id: GO:0005829
      label: cytosol
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-8961846
    review:
      summary: >-
        Reactome TAS annotation for cytosol, from CCNE1 gene transcription
        stimulated by E2F1. This annotation seems to be about the gene product
        being present in cytosol in the context of its transcriptional regulation.
      action: ACCEPT
      reason: >-
        While the Reactome reaction is about transcriptional regulation, cyclin E1
        protein is synthesized in the cytosol. Consistent with cytoplasmic
        localization evidence.
  - term:
      id: GO:0005829
      label: cytosol
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9706390
    review:
      summary: >-
        Reactome TAS annotation for cytosol from RHOBTB3 interaction at trans-Golgi
        network. This is a less well-characterized interaction.
      action: ACCEPT
      reason: >-
        While the RHOBTB3 interaction context is less well characterized for cyclin
        E1, cytosolic presence is consistent with known nucleocytoplasmic shuttling
        of cyclin E.
  - term:
      id: GO:0006468
      label: protein phosphorylation
    evidence_type: IMP
    original_reference_id: PMID:10500095
    review:
      summary: >-
        PMID:10500095 describes Cullin-3 targeting cyclin E for ubiquitination. The
        paper discusses cyclin E phosphorylation as a signal for degradation, and
        cyclin E-CDK2 complex kinase activity, but cyclin E itself does not catalyze
        phosphorylation. Cyclin E1 is a regulatory subunit, not a kinase.
      action: MODIFY
      reason: >-
        Cyclin E1 does not catalyze protein phosphorylation itself. It is a
        non-enzymatic regulatory subunit that activates CDK2. The annotation should
        be modified to reflect that cyclin E1 regulates protein kinase activity
        rather than directly performing phosphorylation. PMID:10500095 discusses
        "cyclin E-Cdk2 complexes" where CDK2 is the catalytic subunit. The paper
        actually focuses on "Cyclin E is an unstable protein that is degraded in a
        ubiquitin- and proteasome-dependent pathway."
      proposed_replacement_terms:
        - id: GO:0045859
          label: regulation of protein kinase activity
      supported_by:
        - reference_id: PMID:10500095
          supporting_text: >-
            Cyclin E is an unstable protein that is degraded in a ubiquitin- and
            proteasome- dependent pathway
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:16109376
    review:
      summary: >-
        PMID:16109376 is about the bromodomain protein Brd4 and P-TEFb, not directly
        about cyclin E1. Brd4 interacts with cyclinT1 and Cdk9. The reference
        appears questionable for a CCNE1 nuclear localization annotation, as the
        paper primarily concerns cyclinT1/Cdk9. However, nuclear localization of
        cyclin E1 is well established by multiple other lines of evidence,
        including UniProt annotation with PMID:7739542 and IDA from PMID:19942931.
      action: ACCEPT
      reason: >-
        Although the specific reference PMID:16109376 may be a curatorial error
        (the paper focuses on Brd4/P-TEFb/cyclinT1/Cdk9 rather than cyclin E1),
        the nuclear localization of CCNE1 itself is unambiguously established.
        UniProt states "SUBCELLULAR LOCATION: Nucleus" with experimental evidence,
        and multiple other IDA annotations confirm nuclear localization
        (PMID:19942931). The annotation conclusion is correct even if the cited
        reference is questionable.
      supported_by:
        - reference_id: PMID:16109376
          supporting_text: >-
            Proteomic analysis revealed that Brd4 interacts with cyclinT1 and Cdk9 that
            constitutes core positive transcription elongation factor b (P-TEFb)
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:9891079
    review:
      summary: >-
        Interaction with BAF155 and BRG1, components of the SWI-SNF chromatin
        remodeling complex. Cyclin E associates with these components and modulates
        BRG1-induced growth arrest.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Generic protein binding is uninformative. The actual finding is a specific
        interaction between cyclin E and SWI-SNF complex components (BAF155, BRG1)
        that may modulate chromatin remodeling during cell cycle progression.
      supported_by:
        - reference_id: PMID:9891079
          supporting_text: >-
            BRG1 and BAF155, mammalian homologs of yeast SWI2 and SWI3, respectively,
            are found in cyclin E complexes and are phosphorylated by cyclin
            E-associated kinase activity
  - term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
    evidence_type: NAS
    original_reference_id: PMID:8207080
    review:
      summary: >-
        NAS annotation from the alternative splicing paper. The paper establishes
        cyclin E as a G1 cyclin that activates CDK2 for S-phase entry.
      action: ACCEPT
      reason: >-
        PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related
        protein kinase cdk2, which is activated shortly before S-phase entry, thus
        defining it as a G1 cyclin." Core function annotation.
      supported_by:
        - reference_id: PMID:8207080
          supporting_text: >-
            Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
            which is activated shortly before S-phase entry, thus defining it as a G1
            cyclin
core_functions:
  - description: >-
      Cyclin E1 functions as a regulatory subunit that binds and activates CDK2
      (cyclin-dependent kinase 2), forming the cyclin E1-CDK2 holoenzyme complex.
      The cyclin E1-CDK2 complex phosphorylates RB1, releasing E2F transcription
      factors to activate S-phase gene expression, thereby driving the G1/S
      transition of the mitotic cell cycle.
    molecular_function:
      id: GO:0016538
      label: cyclin-dependent protein serine/threonine kinase regulator activity
    directly_involved_in:
      - id: GO:1900087
        label: positive regulation of G1/S transition of mitotic cell cycle
    locations:
      - id: GO:0005654
        label: nucleoplasm
    in_complex:
      id: GO:0097134
      label: cyclin E1-CDK2 complex
    supported_by:
      - reference_id: PMID:15838514
        supporting_text: >-
          Cyclin E-Cdk2 has long been considered an essential and master regulator of
          progression through G1 phase of the cell cycle
      - reference_id: PMID:8207080
        supporting_text: >-
          Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
          which is activated shortly before S-phase entry, thus defining it as a G1
          cyclin
references:
  - id: GO_REF:0000033
    title: Annotation inferences using phylogenetic trees
    findings: []
  - id: GO_REF:0000043
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
    findings: []
  - id: GO_REF:0000052
    title: Gene Ontology annotation based on curation of immunofluorescence data
    findings: []
  - id: GO_REF:0000107
    title: Automatic transfer of experimentally verified manual GO annotation data
      to orthologs using Ensembl Compara
    findings: []
  - id: GO_REF:0000120
    title: Combined Automated Annotation using Multiple IEA Methods
    findings: []
  - id: PMID:10330164
    title: Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions with a common
      domain of the p300 coactivator.
    findings: []
  - id: PMID:10500095
    title: Cullin-3 targets cyclin E for ubiquitination and controls S phase in
      mammalian cells.
    findings: []
  - id: PMID:11533444
    title: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7
      ubiquitin ligase.
    findings: []
  - id: PMID:15838514
    title: Cyclin E in normal and neoplastic cell cycles.
    findings: []
  - id: PMID:16109376
    title: The bromodomain protein Brd4 is a positive regulatory component of P-TEFb
      and stimulates RNA polymerase II-dependent transcription.
    findings: []
  - id: PMID:16223725
    title: The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo
      fibroblasts to genomic instability.
    findings: []
  - id: PMID:16431923
    title: The nucleocapsid protein of severe acute respiratory
      syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase
      complex and blocks S phase progression in mammalian cells.
    findings: []
  - id: PMID:16504183
    title: Regulation of the transcription factor FOXM1c by Cyclin E/CDK2.
    findings: []
  - id: PMID:16721056
    title: G1/S Cyclins interact with regulatory subunit of PKA via A-kinase
      anchoring protein, AKAP95.
    findings: []
  - id: PMID:16765349
    title: Increased p21 expression and complex formation with cyclin E/CDK2 in
      retinoid-induced pre-B lymphoma cell apoptosis.
    findings: []
  - id: PMID:17254966
    title: Cdk-inhibitory activity and stability of p27Kip1 are directly regulated
      by oncogenic tyrosine kinases.
    findings: []
  - id: PMID:17254967
    title: p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.
    findings: []
  - id: PMID:17434132
    title: 'Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated
      substrate recognition by SCF ubiquitin ligases.'
    findings: []
  - id: PMID:17525332
    title: ATM and ATR substrate analysis reveals extensive protein networks
      responsive to DNA damage.
    findings: []
  - id: PMID:19470470
    title: RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition
      and increase cell motility.
    findings: []
  - id: PMID:19942931
    title: 'Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates trophoblast cell
      proliferation during human placental development and in preeclampsia.'
    findings: []
  - id: PMID:21092281
    title: HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin
      E-CDK2 interactions and delays cell cycle progression.
    findings: []
  - id: PMID:21540187
    title: Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1
      (INCA1) regulates proliferation and is repressed by oncogenic signaling.
    findings: []
  - id: PMID:21952639
    title: NIRF constitutes a nodal point in the cell cycle network and is a
      candidate tumor suppressor.
    findings: []
  - id: PMID:21988832
    title: Toward an understanding of the protein interaction network of the human
      liver.
    findings: []
  - id: PMID:23083510
    title: miR-16 inhibits the proliferation and angiogenesis-regulating potential of
      mesenchymal stem cells in severe pre-eclampsia.
    findings: []
  - id: PMID:23455922
    title: Interlaboratory reproducibility of large-scale human protein-complex
      analysis by standardized AP-MS.
    findings: []
  - id: PMID:23602568
    title: The protein interaction landscape of the human CMGC kinase group.
    findings: []
  - id: PMID:23853094
    title: Foxp3 protein stability is regulated by cyclin-dependent kinase 2.
    findings: []
  - id: PMID:24358021
    title: Polycomb protein SCML2 regulates the cell cycle by binding and modulating
      CDK/CYCLIN/p21 complexes.
    findings: []
  - id: PMID:25241761
    title: Using an in situ proximity ligation assay to systematically profile
      endogenous protein-protein interactions in a pathway network.
    findings: []
  - id: PMID:25732226
    title: 'MicroRNA-30c-2-3p negatively regulates NF-ÎșB signaling and cell cycle
      progression through downregulation of TRADD and CCNE1 in breast cancer.'
    findings: []
  - id: PMID:25852190
    title: Integrative analysis of kinase networks in TRAIL-induced apoptosis
      provides a source of potential targets for combination therapy.
    findings: []
  - id: PMID:28514442
    title: Architecture of the human interactome defines protein communities and
      disease networks.
    findings: []
  - id: PMID:32296183
    title: A reference map of the human binary protein interactome.
    findings: []
  - id: PMID:33961781
    title: Dual proteome-scale networks reveal cell-specific remodeling of the human
      interactome.
    findings: []
  - id: PMID:34591612
    title: A protein interaction landscape of breast cancer.
    findings: []
  - id: PMID:35271311
    title: 'OpenCell: Endogenous tagging for the cartography of human cellular
      organization.'
    findings: []
  - id: PMID:35512704
    title: Systematic discovery of mutation-directed neo-protein-protein interactions
      in cancer.
    findings: []
  - id: PMID:40205054
    title: Multimodal cell maps as a foundation for structural and functional
      genomics.
    findings: []
  - id: PMID:8207080
    title: Alternative splicing of human cyclin E.
    findings: []
  - id: PMID:8553588
    title: Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a
      complex with cdk2 and p107.
    findings: []
  - id: PMID:8756624
    title: Cyclin-binding motifs are essential for the function of p21CIP1.
    findings: []
  - id: PMID:9840943
    title: Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and
      CDK3, is induced by viral oncoproteins.
    findings: []
  - id: PMID:9891079
    title: 'Cyclin E associates with BAF155 and BRG1, components of the mammalian
      SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest.'
    findings: []
  - id: Reactome:R-HSA-157906
    title: Translocation of Cyclin E:Cdk2 complex to the nucleus
    findings: []
  - id: Reactome:R-HSA-187520
    title: Cyclin E/A:Cdk2-mediated  phosphorylation of p27/p21
    findings: []
  - id: Reactome:R-HSA-187552
    title: Binding of phospho-p27/p21:Cdk2:Cyclin E/A to the SCF(Skp2):Cks1 complex
    findings: []
  - id: Reactome:R-HSA-187574
    title: Degradation of ubiquitinated p27/p21 by the 26S proteasome
    findings: []
  - id: Reactome:R-HSA-187575
    title: Ubiquitination of phospho-p27/p21
    findings: []
  - id: Reactome:R-HSA-188350
    title: CAK-mediated phosphorylation of Cyclin E:Cdk2
    findings: []
  - id: Reactome:R-HSA-188386
    title: Association of Rb with Cyclin E:Cdk2 complexes
    findings: []
  - id: Reactome:R-HSA-188390
    title: Cyclin E:CDK2-mediated phosphorylation of RB1
    findings: []
  - id: Reactome:R-HSA-69005
    title: Cdc6 protein is phosphorylated by CDK
    findings: []
  - id: Reactome:R-HSA-69191
    title: Formation of Cyclin E:Cdk2 complexes
    findings: []
  - id: Reactome:R-HSA-69195
    title: Phosphorylation of Cyclin E:CDK2 complexes by WEE1
    findings: []
  - id: Reactome:R-HSA-69199
    title: Dephosphorylation of Cyclin E:Cdk2 complexes by Cdc25A
    findings: []
  - id: Reactome:R-HSA-8961846
    title: CCNE1 gene transcription is stimulated by E2F1
    findings: []
  - id: Reactome:R-HSA-9706390
    title: RHOBTB3 binds interacting proteins at trans-Golgi network
    findings: []